Medical devices industry venture financing deals in July 2019 total $649.89m globally

16 August 2019 (Last Updated August 16th, 2019 10:09)

Medical devices industry venture financing deals in July 2019 total $649.89m globally

Total medical devices industry venture financing deals in July 2019 worth $649.89m were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 17.9% over the previous month and a drop of 18.5% when compared with the last 12-month average, which stood at $796.95m.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $540.79m. At the country level, the US topped the list in terms of deal value at $540.5m.

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.

The top country in terms of venture financing deals activity in July 2019 was the US with 50 deals, followed by China with four and the UK with three.

In 2019, as of the end of July 2019, medical devices venture financing deals worth $5.82bn were announced globally, marking a decrease of 4.9% year on year.

Medical devices industry venture financing deals in July 2019: Top deals

The top five medical devices industry venture financing deals accounted for 51.4% of the overall value during July 2019.

The combined value of the top five medical devices venture financing deals stood at $334.03m, against the overall value of $649.89m recorded for the month.

The top five medical devices industry deals of July 2019 tracked by GlobalData were:

1) American Cancer Society, Andreessen Horowitz, Data Collective Venture Capital, Verily Life Sciences, GV Management Co, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Section 32 and T. Rowe Price Associates’ $160m venture financing of Freenome

2) The $63m venture financing of Beta Bionics by ArrowMark Partners, Eventide Asset Management, Farallon Capital Management, Perceptive Advisors, RTW Investments and Soleus Capital Management

3) btov Partners, Seroba Life Sciences and Wellington Partners’ $47.03m venture financing of Quanta Dialysis Technologies

4) The $34m venture financing of Orchestra BioMed by Perceptive Advisors, RTW Investments, Soleus Capital Management, SternAegis Ventures and Terumo

5) Mithril Capital Management and Norwest Venture Partners’ venture financing of Neocis for $30m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.